Royal Bank of Canada Reiterates “€65.00” Price Target for MorphoSys (MOR)
MOR has been the topic of several other reports. Independent Research set a €120.00 ($139.53) price target on MorphoSys and gave the stock a neutral rating in a research report on Tuesday, August 7th. JPMorgan Chase & Co. reaffirmed a buy rating and set a price target on shares of MorphoSys in a research report on Thursday, November 1st. Commerzbank set a €107.00 ($124.42) price target on MorphoSys and gave the stock a neutral rating in a research report on Tuesday, November 6th. Goldman Sachs Group set a €86.00 ($100.00) price target on MorphoSys and gave the stock a neutral rating in a research report on Tuesday, November 6th. Finally, Oddo Bhf set a €116.00 ($134.88) price target on MorphoSys and gave the stock a buy rating in a research report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €97.30 ($113.14).
Shares of MOR opened at €98.65 ($114.71) on Monday. MorphoSys has a fifty-two week low of €49.63 ($57.71) and a fifty-two week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Insider Trading
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.